1. Introduction {#sec1-medicines-04-00052}
===============

Many plants have been found as a source of natural antioxidants and base components for new drug formation from their essential oils. The Indian Himalayan region is a large repository of medicinal and aromatic plants. In present study, *C. macrophylla* growing wildly in Uttarakhand Himalaya of India was investigated for chemical composition and pharmacological activity of its essential oils. This plant belonging to family Varbenaceae is an erect, stellate-pubescent, perennial shrub, with stems terete and leaves in sub or unequal pairs on 0.3--1.5 cm long petioles, elliptic-dentate with gland- tipped teeth, glabrescent or so above, 10--20 (--25) × 4--6 (--8) cm while flowers in axillary, 1--3 cm long, peduncled, cymose, corymbose panicles \[[@B1-medicines-04-00052]\]. In this plant, 20 out of 40 species have been reported for their ethno-medical uses. Several members in Chinese and South Asian tradition have been reported as antibiosis, antiphlogosis, and hemostasis drugs \[[@B2-medicines-04-00052]\]. The parts of *C. macrophylla* have been used to treat many ailments like rheumatism and stomach problems. The bark is used to cure cuts and injuries \[[@B3-medicines-04-00052]\]. As an herbal folk medicine, the seeds and roots of this shrub are used for digestive and abdominal troubles in India \[[@B4-medicines-04-00052]\]. 16α, 17-isopropylidene-3-oxophyllocladane (iso-propylidinocalliterpenone) along with calliterpenone and its monoacetate have been reported in methanol extracts from the residual water extracts left after distillation of the essential oil \[[@B5-medicines-04-00052]\]. Analgesic, anti-pyretic, and anti-inflammatory activities have been reported in aqueous and ethanolic extracts of this plant \[[@B6-medicines-04-00052],[@B7-medicines-04-00052]\]. Terpenoids viz; spathulenol (18.1%), germacrene B (13.0%), bicyclogermacrene (11.0%), globulol (3.3%), viridiflorol (2.6%), a-guaiene (2.3%), and g-elemene (2.0%) have been reported in the essential oil of *C. japonica* with different chemical makeup from another species, *C. americana,* growing in Mississippi \[[@B8-medicines-04-00052]\]. We have also reported anti-inflammatory and analgesic activities in aqua-alcoholic leaf extracts of *C. macrophylla* \[[@B9-medicines-04-00052]\].

Tetracyclic diterpenes, calliterpenone, and calliterpenone-monoacetate from the petroleum ether extract, along with β-salinene (41.6--29%) and α-salinene (6--1.7%) in volatile oil of the aerial parts of *C. macrophylla* have been reported \[[@B10-medicines-04-00052],[@B11-medicines-04-00052]\]. In view of its medicinal uses in traditional systems, in the present investigation of different parts of the plant (leaves, pre-mature and mature seeds and fruits) were taken to isolate essential oils and examine the chemo-diversity, antioxidant, and pharmacological activities of this important shrub.

2. Materials and Methods {#sec2-medicines-04-00052}
========================

2.1. Plant Material {#sec2dot1-medicines-04-00052}
-------------------

Fresh aerial parts from *C. macrophylla* were collected during September, October 2011. The plant was taxonomically authenticated by Dr. D.S. Rawat (Assistant Professor & Plant Taxonomist), Department of Biological Science, G.B. Pant University of Agriculture & Technology, Pantnagar. The Herbarium specimen was preserved and deposited in the department.

2.2. Isolation of Essential Oil {#sec2dot2-medicines-04-00052}
-------------------------------

The crushed plant parts were hydro-distilled using Clevenger's type apparatus for over 8 h. The essential oils were extracted by diethyl ether and dried by adding anhydrous Na~2~SO~4~. Removal of solvent yielded 0.20% (*w/v* both in leaves and pre-mature seeds & fruit) and 0.15% (*v/w* in mature seeds & fruits) of essential oils, respectively.

2.3. GC Analysis {#sec2dot3-medicines-04-00052}
----------------

Gas chromatographic analysis was done on a Nucon-GC 5765 system interfaced with a flame ionization detector(FID) and capillary colum (DB-5, 30 m × 0.32 i.d.). The column temperature was induced at 60 °C for the first 5 min and then programmed with the RAM of 3 °C/min up to 210 °C, and finally isothermally for 10 min. Detector temperature was 210 °C and N~2~ was used as carrier gas (flow rate 50 kg/cm^2^). The injection volume of essential oil used was 0.1 µL. The percent composition of oil constituents was determined with the help of a FID.

2.4. GC/MS Analysis {#sec2dot4-medicines-04-00052}
-------------------

The essential oils were analyzed using a Shimadzu GC-2010 interfaced, with a Shimadzu GCMS-QP2010 Plus mass selective detector, having omega wax column (30 m × 0.25 mm, 0.25 μm). The column initial oven temperature was 60 °C and then programmed at 3 °C/min to final oven temperature 240 °C with isothermal for 20 min. The injector temperature was 270 °C. Carrier gas used was helium with a flow rate of 2.42 mL/min and split ratio of 40:1 For MS detection; electron ionization (70 eV) was used as ionization technique. The ion source temperature was 230 °C with 280 °C as the interface temperature. The components were identified by their relative retention times and matching mass spectra with those of standards (main components), from NIST/Wiley library, data of the main system and those published in the literature \[[@B12-medicines-04-00052]\].

2.5. Antioxidant Assay {#sec2dot5-medicines-04-00052}
----------------------

### 2.5.1. Reducing Power Activity {#sec2dot5dot1-medicines-04-00052}

The reducing power was evaluated by the procedures reported earlier \[[@B13-medicines-04-00052]\]. In brief 5, 10, 15, 20, and 25 µL of essential oils (EOs) were added in 2.5 mL of phosphate buffer (200 mM, pH 6.6) and 2.5 mL of 1% K~3~\[FeCN~6~\], followed by 2.5 mL of 10% Cl~3~CCOOH after incubation at 50 °C for 20 min. The content was centrifuged for 10 min at 650 rpm. 5 mL of the supernatant was mixed with 5 mL of distilled water and 1 mL of 0.1% FeCl~3~. The optical density (OD) of the solutions was measured at 700 nm using UV-spectrophotometer (Thermo scientific, Waltham, MA, USA). The same procedure was followed for controls and standards. BHT, catechin, and gallic acid were used as standard antioxidants.

### 2.5.2. Effect on the Chelating Activity of Fe^2+^ {#sec2dot5dot2-medicines-04-00052}

The procedure is based on the Fe^2+^ chelating ability of the antioxidant measured calorimetrically at 562 nm using ferrous ion-ferrozine as a reference complex \[[@B14-medicines-04-00052]\]. 0.1 mL of 2 mM FeCl~2~·4H~2~O and 0.2 mL of 5mM ferrozine were added to 5--25 μL of essential oils followed by methanol to make up the volume to 5 mL. The solutions were homogenized and allowed to react for 10 min. OD was measured at 562 nm. The chelating activity on Fe^2+^ of EOs were compared with that of EDTA (0.01 mM) and citric acid (0.025 M). The following equation was used to calculate the percent of chelating activity. (A~t~ = absorbance of the sample, A~0~ = absorbance of the control at 562 nm).

### 2.5.3. DPPH Radical Scavenging Activity {#sec2dot5dot3-medicines-04-00052}

The scavenging effect on the DPPH radical was evaluated by following the developed and reported procedures \[[@B15-medicines-04-00052]\]. 5, 10, 15, 20, and 25 µL of EOs were mixed with 5 mL of 0.004% freshly prepared DPPH solution in CH~3~OH. The solutions were placed in the dark for 30 min. OD of the samples, standards, and control were read at 517 nm. BHT, catechin, and gallic acid were used as standards. The percent DPPH radical scavenging activity was calculated by the following equation. (A~t~ = absorbance of the sample, A~0~ = absorbance of the control at 517 nm).

### 2.5.4. NO Radical Scavenging Activity {#sec2dot5dot4-medicines-04-00052}

Nitric oxide (NO) obtained from sodium nitroprusside (SNP) was measured by the Griess reagent with the composition of 1% sulfanilamide, 0.1% naphthylethylenediamine dichloride, and 2.0 mL orthophosphoric acid. The scavengers of NO competed with oxygen, leading to reduced production of NO. 2 mL of SNP (10 mM) in phosphate buffer saline (PBS) with pH 7.4 was homogenized with different concentrations (5--25 µL/mL) of EOs dissolved in acetone. The content was incubated at 25 °C for about 150 min. OD of the pink color developed was read at 546 nm. Ascorbic acid was taken as standard \[[@B16-medicines-04-00052]\]. NO scavenging activity was calculated as: (A~t~ = absorbance of sample, A~0~ = absorbance of control at 546 nm).

### 2.5.5. Super Oxide Radical Scavenging Activity {#sec2dot5dot5-medicines-04-00052}

In brief 1 mL nitroblueterazolium (156 mM), 1 mL nicotinamide adenine dinucleotide (468 mM) and 0.1 mL of phenanzinemethosulphate solution (PMS) in 0.1 M of phosphate buffer solution (pH 7.4) was mixed to various concentrations (5--25 μL) of EOs followed by incubation at 25 °C for 5 min. The OD was measured at 560 nm against blank containing all reagents except PMS. Ascorbic acid was taken as standard \[[@B17-medicines-04-00052]\]. The % super oxide radical scavenging activity was calculated as: (A~t~ = absorbance of sample, A~0~ = absorbance of control at 560 nm).

### 2.5.6. OH Radical Scavenging Activity {#sec2dot5dot6-medicines-04-00052}

The hydroxyl (OH) scavenging activities of EOs were evaluated by using the developed protocols \[[@B17-medicines-04-00052]\]. Briefly 60 μL FeSO~4~.7H~2~0 (1 mM), 90 μL aq. 1, 10 phenanthrolein monohydrate (1 mM), 2.4 μL (0.2 M) phosphate buffer (pH 7.8) and 150 μL of H~2~O~2~ (0.17 mM) was added in 1.5 mL of EOs (5--25 µL). OD was measured at 560 nm for samples control and standards (ascorbic acid). The % OH scavenging activity was calculated as: (A~t~ = absorbance of sample, A~0~ = absorbance of the control at 560 nm).

2.6. Evaluation of Pharmacological Activities {#sec2dot6-medicines-04-00052}
---------------------------------------------

Permission from the institutional ethical committee (Registration No. 330/CPCSEA, Dated, 1 Marth 2001, however the experiments were conducted in the month of December 2012) was taken prior to execute the experiments. Swiss albino mice were procured from the Lab Animal Division of the Central Drug Research Institute, Lucknow, U.P. in India. The animals were randomly divided into eleven groups with six mice in each and were kept under standard laboratory conditions. Three concentrations (5%, 10%, and 20%) of EOs were given orally with the dose level of 10 mL/kg body weight. All the concentrations of EOs were separately triturated by addition of small amount of tween-20 and saline water to make the final volume of 10 mL. Ibuprofen, indomethacin, and paracetamol were used as standard drugs and saline water as control.

2.7. Anti-Inflammatory Activity {#sec2dot7-medicines-04-00052}
-------------------------------

### 2.7.1. Carrageenan-Induced Paw Edema {#sec2dot7dot1-medicines-04-00052}

The anti-inflammatory activity of EOs were evaluated according to the protocols reported \[[@B18-medicines-04-00052]\]. Briefly, edema was induced by injecting carrageenan (0.1 mL, 1% w/v in saline) in the sub plantar tissue of the right hind paw of mice. The ninth group was given EOs 5, 10, and 20% as 10 mL/kg body weight, group ten was given ibuprofen (40 mg/kg b. wt.), while group eleven received only saline water. The paw volumes were measured plethysmometrically at 1, 3, and 24 h after the carrageenan injection. It has been reported that formation of edema is a result of synergism between inflammatory mediators which provoke vascular permeability and mediate the blood flow \[[@B19-medicines-04-00052]\]. The decrease in the paw volume in comparison to control was taken as anti-inflammatory effect.

### 2.7.2. Formaldehyde-Induced Inflammatory Activity {#sec2dot7dot2-medicines-04-00052}

This activity of the EOs were studied in HCHO induced arthritis. Briefly, 0.1 mL HCHO (1%) solution was injected in the right hind paw of the mice \[[@B20-medicines-04-00052]\]. The EOs were administered orally every day in the morning during tenure (10 days) of experiments. Ibuprofen suspension (40 mg/kg b. wt.) was used as standard anti-inflammatory drug. The control group was given only saline water. Paw volumes of all the mice were measured plethysmometrically.

2.8. Analgesic Activity {#sec2dot8-medicines-04-00052}
-----------------------

### Acetic Acid-Induced Abdominal Writhing Test

In this activity, the animals were treated with glacial acetic acid intraperitoneally to induce pain sensation \[[@B21-medicines-04-00052]\]. After 1 h, 0.2 mL of EOs, ibuprofen (40 mg/kg b. wt.), and saline water were orally administered. The numbers of writhings were counted for 30 min in each mouse. The reduction of writhing in mice by ibuprofen was compared and the percentage of pain protection was calculated using the following formula: T = treatments (group I--IX); C = Control saline group (X).

2.9. Antipyretic Activity {#sec2dot9-medicines-04-00052}
-------------------------

To evaluate antipyretic activity pyrexia was induced in mice by subcutaneous injection of 20% brewer's yeast *(Sacchromyces cerevisiae)* (10 mg/kg b. wt.) as per the reported protocol \[[@B22-medicines-04-00052]\]. The mice were maintained in a quiet laboratory environment for 18 h in order to raise body temperature. At the 19th hour, the rectal temperature was recorded. After 18 h of injection of yeast, immediately essential oils (5%, 10% and 20%), and paracetamol (33 mg/kg b. wt.) were administered orally. The control group was given only 0.2 mL normal saline. The temperature was monitored at hourly intervals in all the mice up to 3 h and the percentage reduction in rectal temperature was calculated by considering the total fall in temperature to normal level as 100%. A = normal temperature B = Pyrexia temperature C = temp at hourly interval

2.10. Assessment of Toxicity {#sec2dot10-medicines-04-00052}
----------------------------

In order to evaluate the toxic effect of essential oils, different doses (40%, 60%, and 80%) at 10 mL/kg body weight were given to experimental animals. For toxic effect of drug under experiment, the behavioral changes were recorded for 24 h and the numbers of deaths if any were recorded up to 48 h.

2.11. Statistical Analysis {#sec2dot11-medicines-04-00052}
--------------------------

The experimental data generated were represented as mean ± S.E and the results were analyzed using one way analysis of variance. The value of *p* \< 0.05 were considered to be statistically significant.

3. Results and Discussion {#sec3-medicines-04-00052}
=========================

Over 40--53 compounds were identified in CMLEO, CMEO-I, and CMEO-II which contributed to 96.55%, 94.56%, and 95.35% of the total oil, respectively. The constituents identified in CMLEO, were β-selinene (37.51%), phyllocladene (9.76%), caryophelline oxide (7.34%), caryophelline-9-epi (E) (6.23%), longipinocarvone (4.96%), β-caryophelline (3.26%), juniper camphor (3.13%), vulgarone (2.92%), 1, 8-cineole (2.23%), α--muurolol (1.76%), and sphathulenol (1.06%) ([Table 1](#medicines-04-00052-t001){ref-type="table"}). In CMEO-I, the identified constituents β-selinene (44.66%), caryophelline oxide (8.74%), phyllocladene (5.80%), 1,8-cineole (3.10%), juniper camphor (3.03%), longicamphenylone (3.08%), aromadandrene (2.14%), sphathulenol (2.10%), caryophelline-9-epi(E) (1.27%), longipinocarvone (1.17%), β-pinene (1.07%), and vulgarone (1.02%) were major compounds along with other minor ones ([Table 1](#medicines-04-00052-t001){ref-type="table"}). β-selinene (57.01%), phyllocladene (12.38%), caryophelline oxide (5.0%), 9E-epi-caryophelline (3.43%), β-pinene (2.32%) longipinocarvone (2.0%), 1,8-cineole (1.62%), β-caryophelline (1.84%), vulgarone(0.40%), sphathulenol (0.30%), and aromadandrene (0.19%) were identified in CMEO II ([Table 1](#medicines-04-00052-t001){ref-type="table"}).

β-Salinene has been found as a major compound in all the EOs. The oils also showed diversity both in qualitative and quantitative makeup of essential oils. CMEO-I contained longicamphnylone (3.08%), 4-camphenylbutan-2-one (0.80%) cedren-13-ol (0.52%), nopinone (0.50%), hexanoic acid (0.47%), terpinen-4-ol (0.43%), bornyl acetate (0.42%), and leden oxide-I (0.40%) which were absent in other oils. Muurolene-14-oxy-α (2.50%), α-muurolol (1.76%), β-copaen-4-α-ol (1.03%), globulol (0.42%), β-oplopenone (0.33%) etc were found only in CMLEO, while 5-octen-2-one (0.53%), β-ocimene (0.31%), α-pinene (0.40%), and khusinol (0.10%) were identified only in CMEO-II ([Table 1](#medicines-04-00052-t001){ref-type="table"}).

3.1. Antioxidant Assay {#sec3dot1-medicines-04-00052}
----------------------

### 3.1.1. Reducing Power {#sec3dot1dot1-medicines-04-00052}

The essential oils showed good reducing activity as the function of concentration compared to standard antioxidants (BHT, catechin, and gallic acid). CMEO-II showed the highest reducing property of the extracts ([Figure 1](#medicines-04-00052-f001){ref-type="fig"}).

### 3.1.2. Ability of Chelating Fe^2+^ Ion {#sec3dot1dot2-medicines-04-00052}

As shown in [Figure 2](#medicines-04-00052-f002){ref-type="fig"}, all the EOs revealed good Fe^2+^ chelating with maximum chelating values of 63.82% recorded for CMEO-II, at 25 µL/mL of dose level compared to standard antioxidants.

### 3.1.3. DPPH Radical Scavenging Activity {#sec3dot1dot3-medicines-04-00052}

The EO showed good to moderate DPPH radical scavenging activity. CMEO-II was a better DPPH radical scavenger than CMLEO and CMEO-I, compared to standard antioxidant viz. BHT, catechin, and gallic acid ([Figure 3](#medicines-04-00052-f003){ref-type="fig"}). DPPH scavenging activity was observed between 55.67--62.63% at highest concentration (25 µL) among the oils. However, the standard showed slightly stronger activity in the range of 69.39--73.58%.

### 3.1.4. Superoxide Radical Scavenging Activity {#sec3dot1dot4-medicines-04-00052}

CMEO-II, CMEO-I, and CMLEO exhibited good superoxide scavenging activity with maximum at higher concentration. CMLEO-II revealed highest scavenging activity (56.98 ± 0.630%) followed by CMLEO (56.49 ± 0.412%) and CMEO-I (53.13 ± 0.724%), respectively, as compared to ascorbic acid (60.76 ± 0.313%) ([Figure 4](#medicines-04-00052-f004){ref-type="fig"}).

### 3.1.5. NO Radical Scavenging Activity {#sec3dot1dot5-medicines-04-00052}

The EOs were good NO radical scavengers but moderate in comparison to the standard, ascorbic acid. CMEO-II was the strongest NO scavenger among the oils and scavenged 43.51 ± 0.329--70.68 ± 0.115% NO radical from 5 µL to 25 µL ([Figure 5](#medicines-04-00052-f005){ref-type="fig"}).

### 3.1.6. OH Radical Scavenging Activity {#sec3dot1dot6-medicines-04-00052}

The oils exhibited OH radical scavenging in a dose-dependent manner similar to DPPH, NO, and superoxide methods. Maximum scavenging activity was observed at the concentration level of 25 μL in ascorbic acid (68.48 ± 0.708%) followed by CMEO-II (64.4 ± 0.900%), CMLEO (61.22 ± 0.340%), and CMEO-I (57.03 ± 0.520%), respectively ([Figure 6](#medicines-04-00052-f006){ref-type="fig"}).

The results obtained as IC~50~ values for scavenging and chelating activity of the EOs indicated their efficiency against oxidative stress as well as free radicals. CMEO-II showed the minimum IC~50~ value in all the activity tests among the oils and the highest antioxidant activity, but was moderate in comparison to the standards ([Table 2](#medicines-04-00052-t002){ref-type="table"}). The IC~50~ values for chelating activity were found in the order of EDTA (IC~50~ = 9.27 ± 0.11 µg/mL), followed by citric acid (IC~50~ = 9.42 ± 0.95 µg/mL), CMEO-II (IC~50~ =11.49 ± 0.87 µL/mL), CMEO-I (IC~50~ = 13.42 ± 0.17 µL/mL), and CMLEO (IC~50~ = 14.38 ± 0.27 µL/mL). The DPPH radical is a highly reactive species and used for evaluation of free radical scavenging activity of antioxidants. It accepts an electron and a hydrogen to become a stable diamagnetic molecule \[[@B18-medicines-04-00052],[@B19-medicines-04-00052]\]. The scavenging effect of the EOs and standards with the DPPH radical were observed in the following order: gallic acid (IC~50~ = 7.95 ± 0.11 µg/mL) \> catechin (IC~50~ = 8.18 ± 0.11 µg/mL) \> BHT (8.55 ± 0.10 µg/mL) \> CMEO-II (IC~50~ =15.66 ± 0.03 µL/mL) \> CMLEO (IC~50~ =18.35 ± 0.18 µL/mL) \> CMEO-I (IC~50~ = 20.19 ± 0.11 µL/mL). It has been reported earlier that the plant-derived products mitigate the harmful effects produced by nitric oxide radicals in human body \[[@B20-medicines-04-00052],[@B21-medicines-04-00052]\]. In the present investigation, the level of nitric oxide was decreased with increased concentration of the EOs. CMEO-II had the strongest anti-radical activity with the IC~50~ value 7.37 ± 0.11 µL/mL, which was comparable to ascorbic acid ([Table 2](#medicines-04-00052-t002){ref-type="table"}). It has been reported that nitric oxide production becomes high in tumor tissues, plasma, and other physiological and pathological processes \[[@B23-medicines-04-00052]\]. The superoxide anion is a forerunner of reactive oxygen species and produces destructive effects to cellular systems \[[@B24-medicines-04-00052]\]. Photochemically generated O~2~^.^ reduces to NBT and forms blue formazan \[[@B25-medicines-04-00052]\]. It has been observed that inhibition of formation of the blue formazan is a function of the concentration of the essential oils, which were found to be efficient scavengers of superoxide radicals and their activity were moderate compared to ascorbic acid. Damage to the adjacent biomolecules by the most reactive hydroxyl radical has been reported along with oxidative damage to DNA, lipids, and proteins \[[@B26-medicines-04-00052],[@B27-medicines-04-00052]\]. The present study reveals the maximum hydroxyl radical scavenging effect of essential oils at the concentration level of 25 µL/mL.

All the essential oils had low amounts of phenolic compounds but showed good antioxidant activity. The diversified mono- and sesquiterpenoids present in the complex mixture of essential oils might be responsible for the good antioxidant activity because of synergetic effects of the constituents. This can be evidenced by a report which says that antioxidant capacity is affected by other bioactive compounds and could involve synergistic effects \[[@B28-medicines-04-00052]\].

3.2. Anti-Inflammatory Activity {#sec3dot2-medicines-04-00052}
-------------------------------

### 3.2.1. Mice Paw Edema (Carrageenan-Induced) {#sec3dot2dot1-medicines-04-00052}

A gradual increase in carrageenan-induced hind paw edema volume of mice in the control and sample groups was observed. However, in CMEO-II, CMLEO, CMEO-I, and standard drug treated groups, a significant reduction in the volume of edema was observed ([Table 3](#medicines-04-00052-t003){ref-type="table"}). Other concentrations of oils showed moderate activity in comparison to the standard drug. The inhibitory effect of the oils was observed to be the highest with a dose level of 20% oils at 24 h, as 21.16% in CMEO-II, 17.78% in CMLEO, and 16.30% in CMEO-I, whereas ibuprofen produced a 37.17% reduction in the same experimental conditions ([Table 3](#medicines-04-00052-t003){ref-type="table"}).

### 3.2.2. Formaldehyde-Induced Inflammatory Activity {#sec3dot2dot2-medicines-04-00052}

CMEO-II, CMLEO, and CMEO-I resulted in moderate inhibition in paw volume compared to ibuprofen. CMEO-II revealed the greatest inhibition in paw volume (2.23 mm^3^ on day 1 and 2.20 mm^3^ on day 10), followed by CMLEO (2.3 mm^3^ on day 1 and 2.22 mm^3^ on day 10) and CMEO-I (2.26 mm^3^ on day 1 and 2.24 mm^3^ on day 10) at 20% dose level. The inhibition property was observed in a dose-dependent manner ([Table 4](#medicines-04-00052-t004){ref-type="table"}).

3.3. Analgesic Activity {#sec3dot3-medicines-04-00052}
-----------------------

CMEO-II, CMLEO, and CMEO-I showed significant analgesic activity with 35.33%, 30.04%, and 25.72% inhibition at 20% dose level, respectively, compared to the standard drug, ibuprofen, which inhibited 43.99% ([Table 5](#medicines-04-00052-t005){ref-type="table"}). Prostaglandins have been reported to enhance inflammation and pain by increasing capillary permeability \[[@B29-medicines-04-00052]\]. An analgesic substance reduces the number of writhings due to pain. It has been reported that analgesic drugs inhibit the synthesis of prostaglandins \[[@B30-medicines-04-00052]\]. It can be inferred that the EOs of *C. macophylla* are responsible for the reduction of prostaglandin synthesis and exhibit analgesic properties.

3.4. Antipyretic Activity {#sec3dot4-medicines-04-00052}
-------------------------

All the oils revealed significant antipyretic activity. Yeast significantly induced pyrexia by increasing rectal temperature 18 h after injection. The reduction in temperature was observed up to 3 h. A maximum reduction in pyrexia of 1.05 °C (96.33%) was observed in paracetamol-treated group up to 24 h. The uniform fall in temperature up to 24 h was observed by increasing the dose ([Table 6](#medicines-04-00052-t006){ref-type="table"}). It has been reported in previous studies that the lipid per oxidation process is enhanced by increasing body temperature \[[@B31-medicines-04-00052]\].

Infection in the body is a cause of fever or other diseased states like tissue damage, inflammation, and graft rejection etc. \[[@B32-medicines-04-00052]\]. Regulation of body temperature requires equilibrium between the production and dissipation of heat. The present study exhibited significant antipyretic properties of EOs on brewer's yeast-induced pyrexia in mice. The antipyretic activity of EOs may be due to interference on the biosynthesis of prostaglandins. The result of this study revealed that *C. macrophylla* can be beneficial to treat inflammations, pain, and fever. These activities might be due to presence of a complex mixture of terpenoids.

The essential oil of *C. macrophylla* showed activities in various degrees against inflammation, pain, and fever. According to the research, higher levels of prostaglandin, particularly PGE2, produce inflammation, pain, and fever because of cyclooxygenase activation \[[@B33-medicines-04-00052]\]. As a result, we suppose that some active constituents of the essential oils could inhibit cyclooxygenase activity. It has been reported that the carrageenan-induced paw edema in rats is susceptible to cyclooxygenase (COX) inhibitors. These have been used as non-steroidal anti-inflammatory agents and are also suitable for assessing the anti-oedematous effects of natural products \[[@B34-medicines-04-00052],[@B35-medicines-04-00052]\].

3.5. Acute Toxicity {#sec3dot5-medicines-04-00052}
-------------------

Essential oils from parts of *C. macrophylla* neither cause any changes in behavior nor any death of mice under experimentation during the period of observation. It was thus considered that the EOs were practically non-toxic.

4. Conclusions {#sec4-medicines-04-00052}
==============

The EOs from *C. macrophylla* showed a qualitative and quantitative make-up of constituents. The oils also showed different pharmacological activities. From the results, it could be inferred that the essential oils might be used as drugs for treatment of inflammation, fever, and pain in traditional systems of medicine with scientific knowledge. Clinically, this herb can be a good source of herbal medicine for the treatment of diseases indigenously. The study will also help to generate a database of species which can be exploited scientifically and judiciously in the future by local people and so that ecological balance is maintained.
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medicines-04-00052-t001_Table 1

###### 

Essential oil composition from different parts of *Callicarpa macropylla*.

  S.N.        Compounds Name                         KI/RI       FID %               
  ----------- -------------------------------------- ----------- ----------- ------- -------
  1           hex-2*E*-enal                          850         0.20        \-      \-
  2           α-pinene                               933         0.06        \-      0.40
  3           β-pinene                               943         0.53        1.07    2.32
  4           1-octene-3one                          943         0.02        0.12    0.02
  5           3-octanone                             952         0.10        0.12    0.06
  6           banzaldehide                           960         0.14        \-      \-
  7           sabinene                               972         0.17        0.40    0.25
  8           hexanoic acid                          979         \-          0.47    \-
  9           myrcene                                991         \-          \-      0.04
  10          hex-3*Z*-ethyl acetate                 1008        0.01        \-      \-
  11          p-cymene                               1025        0.13        0.41    0.14
  12          limonene                               1030        \-          0.15    0.12
  13          1,8-cineole                            1032        2.23        3.10    1.62
  14          β-ocimene                              1046        \-          \-      0.31
  15          2-nonanone                             1052        0.02        \-      \-
  16          *trans*-2-octenal                      1067        \-          0.27    \-
  17          *cis* linalool oxide                   1069        \-          0.21    \-
  18          *trans* linalool oxide                 1086        \-          0.15    \-
  19          linalool                               1101        0.20        0.86    \-
  20          nopinone                               1139        \-          0.50    \-
  21          sabina ketone                          1154        0.03        \-      \-
  22          pinocarvone                            1164        \-          0.64    0.45
  23          terpinen-4-ol                          1180        \-          0.43    \-
  24          myrtenal                               1197        0.23        0.74    0.20
  25          1-butyryl-1,2,3,6-tetrahydropyridine   1249        0.05                
  26          3,9-dodecadiyn                         1249        0.37        \-      \-
  27          bornyl acetate                         1285        \-          0.42    \-
  28          leden oxide (I)                        1293        \-          0.40    \-
  29          myrtenal acetate                       1326        \-          0.19    \-
  30          α-copaene                              1375        0.35        \-      0.27
  31          β-elemene                              1390        0.98        0.82    0.61
  32          β-cubebene                             1392        0.10        0.09    0.48
  33          α-gurjunene                            1406        0.50        0.95    0.15
  34          nopyl acetate                          1413        \-          0.26    \-
  35          β-caryophelline                        1424        3.26        \-      1.84
  36          (*E*) caryophellene                    1424        0.44        \-      0.11
  37          aromadandrene                          1438        \-          2.14    0.19
  38          4-camphenylbutan-2-one                 1451        \-          0.80    \-
  39          α-humulene                             1454        \-          \-      0.14
  40          aromadendrene oxide II                 1462        0.43        0.46    0.25
  41          9*E*-epi-caryophelline                 1464        6.23        1.27    3.43
  42          α-selinene                             1474        0.26                
  43          α-cubebene                             1480        0.11        \-      \-
  44          ar-curcumene                           1480        0.19        0.10    0.14
  45          β-selinene                             1492        37.51       44.66   57.01
  46          amorphene                              1502        0.41        \-      \-
  47          perhydropyrene                         1502                    0.37    
  48          caryophelline oxide                    1507        7.34        8.74    5.0
  49          δ-cadinine                             1518        0.85        0.41    0.59
  50          *trans*-calamene                       1527        0.35        0.15    0.31
  51          globulol                               1530        0.42        \-      \-
  52          Z-α-bisaboline epoxide                 1531                    0.21    
  53          α-agarofuron                           1548        \-          0.40    \-
  54          (*E*)-nerolidol                        1561        \-          0.20    \-
  55          longicamphenylone                      1563        \-          3.08    \-
  56          longipinocarvone                       1569        4.96        1.17    2.0
  57          sphathulenol                           1576        1.06        2.10    0.30
  58          β-copaen-4 α-ol                        1590        1.03        \-      \-
  59          *trans* longipinocarveol               1590        0.63        0.71    \-
  60          fokienol                               1596        0.38        0.31    \-
  61          salvial-4 (14)-en-1-one                1596        0.73        \-      \-
  62          β-oplopanone                           1607        0.33                
  63          humulene epoxide II                    1613        0.21        \-      \-
  64          *Z*-3-hexadecane-7-yne                 1637        \-          0.31    \-
  65          solavetivone                           1645        0.99        0.30    0.40
  66          cedren-13-ol                           1646        \-          0.52    \-
  67          vulgarone                              1649        2.92        1.02    0.40
  68          α-muurolol                             1651        1.76        \-      \-
  69          cadalene                               1677        \-          0.32    \-
  70          khusinol                               1679        \-          \-      0.10
  71          juniper camphor                        1696        3.13        3.03    \-
  72          *cis*-lanceol                          1760        0.12        \-      \-
  73          14-oxy α-muurolene                     1767        2.50        \-      \-
  74          phyllocladene                          1789        9.76        5.80    12.38
  75          cupressene                             1880        \-          0.47    \-
  76          5-octen-2-one                          1932                            0.53
  77          androsta-4,16-dien-3-one               1933        0.71        0.50    0.70
  78          androsta-3,5-dien-7-one                1933        0.55        0.26    0.32
  79          6-androstanone                         1940                            0.13
  80          n-hexadecanoic acid                    1977                            0.43
  81          9Z,12Z,15Z-octadecatrien-1-ol          2077        0.20                
  82          pimara-7,15-dien-3-one                 2097        0.36        0.16    0.24
  83          thunbergol                             2211        \-          0.98    0.23
  84          andrographolide                        2944                    0.84    0.74
  **Total**   **96.55**                              **94.56**   **95.35**           

S.N. = Serial number.:, KI/RI= Kovat indicest/retention indices.

medicines-04-00052-t002_Table 2

###### 

Antioxidant properties in terms of IC~50~ values in essential oils from different areal parts of *C. macrophylla.*

  Extracts            (IC ~50~ in (µL/µg)/mL)/R^2^   \% Absorbance (Reducing Power)                                                                                                                                                    
  ------------------- ------------------------------ -------------------------------- ----------------- --------------- -------------- --------------- ---------------- --------------- -------------- --------------- --------------- ---------------
  **CMLEO**           18.35 ± 0.18                   0.933 ± 0.003                    10.61 ± 0.02      0.941 ± 0.000   18.58 ± 0.19   0.956 ± 0.006   16.06 ± 0.16     0.963 ± 0.006   14.38 ± 0.27   0.913 ± 0.009   0.426 ± 0.004   0.602 ± 0.000
  **CMEO-I**          20.29 ± .11                    0.960 ± 0.06                     11.18 ± 0.06      0.95 ± 0.004    20.79 ± 0.30   0.954 ± 0.005   18.59 ± 0.25     0.960 ± 0.006   13.42 ± 0.17   0.950 ± 0.004   0.411 ± 0.003   0.573 ± 0.000
  **CMEO-II**         15.66 ± 0.03                   0.961 ± 00.005                   **7.37 ± 0.11**   0.922 ± 0.002   17.49 ± 0.13   0.954 ± 0.015   14\. 59 ± 0.18   0.956 ± 0.016   11.49 ± 0.87   0.979 ± 0.006   0.450 ± 0.004   0.418 ± 0.000
  **BHT**             8.55 ± 0.10                    0.947 ± 0.005                    NA                NA              NA             NA              NA               NA              NA             NA              0.55 ± 0.008    0.735 ± 0.009
  **Catechin**        8.18 ± 0.11                    0.950 ± 0.004                    NA                NA              NA             NA              NA               NA              NA             NA              0.455 ± 0.006   0.623 ± 0.004
  **Gallic Acid**     7.95 ± 0.11                    0.964 ± 0.004                    NA                NA              NA             NA              NA               NA              NA             NA              0.575 ± 0.003   0.715 ± 0.003
  **Ascorbic acid**   NA                             NA                               7.72 ± 0.19       0.942 ± 0.002   15.03 ± 0.13   0.951 ± 0.007   11.22 ± 0.30     0.960 ± 0.017   NA             NA              NA              NA
  **EDTA**            NA                             NA                               NA                NA              NA             NA              NA               NA              9.27 ± 0.11    0.955 ± 0.003   NA              NA
  **Citric Acid**     NA                             NA                               NA                NA              NA             NA              NA               NA              9.42 ± 0.95    0.981 ± 0.021   NA              NA

*R*^2^ = linear regression factor, NA = not applicable.

medicines-04-00052-t003_Table 3

###### 

Effect of essential oils from *C. macrophylla* on carrageenan-induced paws edema.

  Group   Treatment   Doses (0.2 mL)    Paw Volume (in mm^3^)   \% Inhibition                                 
  ------- ----------- ----------------- ----------------------- ------------------ ------------------ ------- -------
  I       CMLEO       5%                2.34 ± 0.01             2.29 ± 0.02^b^     2.23 ± 0.02 ^ab^   2.14    4.7
  II      CMLEO       10%               2.31 ± 0.03 ^a^         2.21 ± 0.02 ^ab^   2.12 ± 0.01 ^ab^   4.33    8.23
  III     CMLEO       20%               2.25 ± 0.02 ^ab^        2.05 ± 0.02 ^ab^   1.85 ± 0.03 ^ab^   8.89    17.78
  IV      CMEO-II     5%                2.29 ± 0.01 ^a^         2.19 ± 0.02 ^ab^   2.14 ± 0.03 ^ab^   4.37    6.55
  V       CMEO-II     10%               2.38 ± 0.02             2.30 ± 0.02 ^b^    2.21 ± 0.02 ^ab^   3.36    7.14
  VI      CMEO-II     20%               2.41 ± 0.02             2.17 ± 0.02 ^ab^   1.90 ± 0.05 ^ab^   9.96    21.16
  VII     CMEO-I      5%                2.32 ± 0.03 ^a^         2.29 ± 0.03 ^b^    2.21 ± 0.02 ^ab^   1.29    4.74
  VIII    CMEO-I      10%               2.26 ± 0.02 ^ab^        2.20 ± 0.02 ^ab^   2.15 ± 0.03 ^ab^   2.65    4.87
  IX      CMEO-I      20%               2.27 ± 0.02 ^a^         2.08 ± 0.03a ^b^   1.90 ± 0.03 ^ab^   8.37    16.3
  X       Control     \-                2.40 ± 0.02             2.33 ± 0.01        2.32 ± 0.01        2.92    3.33
  XI      Ibuprofen   40 mg/kg b. wt.   2.34 ± 0.01 ^a^         1.73 ± 0.02 ^a^    1.47 ± 0.02 ^a^    26.07   37.17

^a^ = Significant (*p* \< 0.05) as compared to control, ^b^ = Significant (*p* \< 0.05) as compared to Ibuprofen. % = Percent reduction in paw volume at different times.

medicines-04-00052-t004_Table 4

###### 

Effect of essential oils from *C. macrophylla* on formalin-induced mice paw edema.

  Group   Treatment   Dose           Volume of Paw Edema (in mm^3^)                                                                                                                                                                             
  ------- ----------- -------------- -------------------------------- ------------------ ----------------- ------------------ ------------------ ------------------ ------------------ ------------------- ------------------ ----------------- ------------------
  I       CMLEO       5% (0.2 mL)    2.28 ± 0.02                      2.36 ± 0.02 ^ab^   2.37 ± 0.04 ^b^   2.42 ± 0.04 ^b^    2.41 ±0.04 ^b^     2.40 ± 0.04 ^b^    2.40 ± 0.04 ^b^    2.39 ± 0.04 ^b^     2.39 ± 0.03 ^b^    2.36 ± 0.03 ^b^   2.36 ± 0.04 ^b^
  II      CMLEO       10% (0.2 mL)   2.23 ± 0.03                      2.26 ± 0.02 ^ab^   2.31 ± 0.03 ^b^   2.35 ± 0.04 ^a^    2.34 ±0.03 ^b^     2.32 ± 0.03 ^b^    2.32 ± 0.03 ^b^    2.31 ± 0.03 ^b^     2.31 ± 0.03 ^b^    2.31 ± 0.03 ^b^   2.30 ± 0.03 ^b^
  III     CMLEO       20% (0.2 mL)   2.23 ± 0. 02                     2.25 ± 0.02 ^ab^   2.29 ± 0.02 ^b^   2.30 ± 0.04 ^a^    2.29 ± 0.04 ^ab^   2.27 ± 0.03 ^a^    2.26 ± 0.03 ^ab^   2.25 ± 0. 02 ^ab^   2.24 ± 0.02 ^a^    2.22 ± 0.02 ^a^   2.22 ± 0.02 ^b^
  IV      CMEO -II    5% (0.2 mL)    2.27 ± 0.03                      2.30 ± 0.02 ^ab^   2.36 ± 0.04 ^b^   2.40 ± 0.05 ^ab^   2.39 ± 0.05 ^b^    2.38 ± 0.05 ^b^    2.38 ± 0.04 ^b^    2.38 ± 0.03 ^b^     2.37 ± 0.03 ^b^    2.36 ± 0.03 ^b^   2.36 ± 0.03 ^a^
  V       CMEO-II     10% (0.2 mL)   2.24 ± 0.03                      2.27 ± 0.02 ^ab^   2.34 ± 0.04 ^b^   2.38 ± 0.04 ^ab^   2.37 ± 0.04 ^b^    2.36 ± 0.03 ^b^    2.35 ± 0.03 ^b^    2.33 ± 0.03 ^b^     2.32 ± 0.02 ^b^    2.31 ± 0.02 ^b^   2.30 ± 0.02 ^b^
  VI      CMEO-II     20% (0.2 mL)   2.23 ± 0.02                      2.24 ± 0.02 ^ab^   2.26 ± 0.02 ^a^   2.28 ± 0.03 ^a^    2.26 ± 0.03 ^a^    2.25 ± 0.02 ^a^    2.24 ± 0.02 ^ab^   2.24 ± 0.02 ^ab^    2.22 ± 0.03 ^a^    2.21 ± 0.02 ^a^   2.20 ± 0.03 ^a^
  VII     CMEO-I      5% (0.2 mL)    2.28 ± 0.02                      2.29 ± 0.02 ^ab^   2.37 ± 0.03 ^b^   2.42 ± 0.04 ^b^    2.41 ± 0.03 ^b^    2.41 ± 0.03 ^b^    2.41 ± 0.03 ^b^    2.41 ± 0.02 ^b^     2.41 ± 0.02 ^b^    2.41 ± 0.02 ^b^   2.40 ± 0.02 ^b^
  VIII    CMEO-I      10% (0.2 mL)   2.26 ± 0.03                      2.29 ± 0.02 ^ab^   2.32 ± 0.03 ^b^   2.36 ± 0.04 ^a^    2.35 ± 0.03 ^b^    2.35 ±0.03 ^b^     2.34 ± 0.02 ^b^    2.33 ± 0.03 ^b^     2.35 ± 0.03 ^b^    2.33 ± 0.03 ^b^   2.33 ± 0.03 ^b^
  IX      CMEO-I      20% (0.2 mL)   2.26 ± 0.02                      2.27 ± 0.02 ^ab^   2.29 ± 0.03 ^b^   2.31 ± 0.03 ^a^    2.30 ± 0.02 ^ab^   2.29 ± 0.02 ^ab^   2.27 ± 0.01 ^ab^   2.27 ± 0.02 ^ab^    2.25 ± 0.02 ^ab^   2.24 ± 0.02 ^a^   2.24 ± 0.02 ^ab^
  X       Control     (0.2 mL)       2.13 ± 0.02                      2.17 ± 0.04        2.38 ± 0.03       2.52 ± 0.04        2.44 ± 0.02        2.39 ± 0.01        2.38 ± 0.02        2.38 ± 0.01         2.36 ± 0.01        2.36 ± 0.02       2.37 ± 0.03
  XI      Ibuprofen   10 mg/kg       2.11 ± 0.02                      2.13 ± 0.02 ^a^    2.19 ±0.01 ^a^    2.27 ± 0.01 ^a^    2.21 ± 0.02 ^a^    2.19 ± 0.01 ^a^    2.15 ± 0.01 ^a^    2.16 ± 0.01 ^a^     2.17 ± 0.01 ^a^    2.19 ± 0.01 ^b^   2.15 ± 0.02 ^a^

^a^ = Significant (*p* \< 0.05) as compared to control, ^b^ = Significant (*p* \< 0.05) as compared to Ibuprofen.

medicines-04-00052-t005_Table 5

###### 

Effect of essential oils from *C. macophylla* on acetic acid induced writhing in mice.

  Group   Treatment   Doses             Writhing Counts      \% Writhings   Inhibition (%)
  ------- ----------- ----------------- -------------------- -------------- ----------------
  I       CMLEO       5%                115.83 ± 8.06 ^ab^   83.53          16.47
  II      CMLEO       10%               107.00 ± 4.52 ^ab^   77.16          22.84
  III     CMLEO       20%               95.00 ± 9.01 ^ab^    69.95          31.49
  IV      CMEO -II    5%                112.33 ± 5.28 ^ab^   81             18.99
  V       CMEO-II     10%               104.33 ± 7.09 ^ab^   75.24          24.76
  VI      CMEO-II     20%               85.33 ± 7.74 ^a^     61.53          38.46
  VII     CMEO-I      5%                119.67 ± 7.09 ^ab^   86.3           13.7
  VIII    CMEO-I      10%               111.67 ± 6.12 ^ab^   80.53          19.47
  IX      CMEO-I      20%               103.00 ± 4.86 ^ab^   74.28          25.72
  X       Control     \-                138.67 ± 5.75        \-             \-
  XI      Ibuprofen   40 mg/kg b. wt.   77.67 ± 6.86 ^a^     56.01          43.99

^a^ = Significant (*p* \< 0.05) as compared to control, ^b^ = Significant (*p* \< 0.05) as compared to Ibuprofen.

medicines-04-00052-t006_Table 6

###### 

Effect of essential oils from *C. macrophylla* on brewer's yeast-induced pyrexia in mice.

  Group   Treatment     Dose           Body Temperature (°C)   Body Temperature After Administration of Drug (°C)   \% Reduction in Body Temperature                                                           
  ------- ------------- -------------- ----------------------- ---------------------------------------------------- ---------------------------------- ------------------- ------------------- ------- ------- -------
  I       CMLEO         5% (0.2 mL)    37.57 ± 0.05            38.57 ± 0.04                                         38.29 ± 0.03 ^b^                   38.18 ± 0.04 ^ab^   38.13 ± 0.03 ^b^    28      39      44.00
  II      CMLEO         10% (0.2 mL)   37.47 ± 0.03            38.49 ± 0.03 ^b^                                     38.15 ± 0.03 ^ab^                  38.01 ± 0.04 ^ab^   37.94 ± 0.04 ^ab^   33.33   47.05   53.92
  III     CMLEO         20% (0.2 mL)   37.56 ± 0.02 ^a^        38.58 ± 0.04                                         37.99 ± 0.03 ^ab^                  37.86 ± 0.04 ^ab^   37.77 ± 0.05 ^ab^   57.84   70.59   79.41
  IV      CMEO-II       5% (0.2 mL)    37.55 ± 0.03            38.56 ± 0.03                                         38.27 ± 0.02 ^b^                   38.12 ± 0.03 ^ab^   38.08 ± 0.03 ^ab^   28.71   43.56   47.52
  V       CMEO-II       10% (0.2 mL)   37.49 ± 0.04            38.51 ± 0.03                                         38.14 ± 0.04 ^ab^                  37.97 ± 0.04 ^ab^   37.90 ± 0.04 ^ab^   36.27   52.94   59.8
  VI      CMEO-II       20% (0.2 mL)   37.51 ± 0.04            38.55 ± 0.03                                         37.89 ± 0.04 ^ab^                  37.73 ± 0.02 ^ab^   37.63 ± 0.03 ^a^    63.46   78.85   88.46
  VII     CMEO-I        5% (0.2 mL)    37.48 ± 0.03            38.46 ± 0.03 ^b^                                     38.19 ± 0.03 ^ab^                  38.12 ± 0.04 ^ab^   38.06 ± 0.04 ^ab^   27.55   34.69   40.82
  VIII    CMEO-I        10% (0.2 mL)   37.52 ± 0.02            38.53 ± 0.03                                         38.20 ± 0.04 ^ab^                  38.07 ± 0.04 ^ab^   38.00 ± 0.05 ^ab^   32.67   45.54   52.47
  IX      CMEO-I        20% (0.2 mL)   37.49 ± 0.02            38.54 ± 0.02                                         37.97 ± 0.02 ^ab^                  37.87 ± 0.02 ^ab^   37.76 ± 0.05 ^ab^   54.28   63.81   74.29
  X       Control       (0.2 mL)       37.46 ± 0.02            38.50 ± 0.03                                         38.36 ± 0.04                       38.30 ± 0.03        38.22 ± 0.03        13.46   19.23   26.92
  XI      Paracetamol   33.0 mg/kg     37.50 ± 0.03            38.59 ± 0.04 ^a^                                     37.75 ± 0.04 ^a^                   37.61 ± 0.03 ^a^    37.54 ± 0.04 ^a^    77.06   89.91   96.33

^a^ = Significant (*p* \< 0.05) as compared to control, ^b^ = Significant (*p* \< 0.05) as compared to Paracetamol.
